TCRR - TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
- TCR2 Therapeutics press release ( NASDAQ: TCRR ): Q2 GAAP EPS of -$0.82 misses by $0.02 .
- TCR 2 ended the second quarter of 2022 with $206.2 million in cash, cash equivalents, and investments compared to $265.6 million as of December 31, 2021.
For further details see:
TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02